Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price objective on shares of Evogene from $30.00 to $12.00 and set a buy rating for the company in a research report on Friday, August 23rd.

Evogene Trading Up 1.2 %

Shares of EVGN opened at $2.54 on Monday. The stock has a 50 day moving average of $3.72 and a 200 day moving average of $5.88. The company has a market capitalization of $104.69 million, a price-to-earnings ratio of -5.52 and a beta of 1.40. Evogene has a 12 month low of $2.29 and a 12 month high of $10.40.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets raised its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.